Patents Assigned to Juno Therapeutics, Inc.
-
Publication number: 20230149462Abstract: Provided are methods and uses related to adoptive cell therapy involving the administration of doses of cells, such as T cells, for treating disease and conditions, including certain plasma cell malignancies. The cells express recombinant receptors such as chimeric antigen receptors (CARs) specific to B-cell maturation antigen (BCMA). In some embodiments, the methods are for treating subjects with multiple myeloma (MM).Type: ApplicationFiled: April 9, 2021Publication date: May 18, 2023Applicant: Juno Therapeutics, Inc.Inventors: Mariana Cota STIRNER, Mirna MUJACIC, Todd DEVRIES
-
Publication number: 20230149458Abstract: Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.Type: ApplicationFiled: June 22, 2022Publication date: May 18, 2023Applicant: Juno Therapeutics, Inc.Inventors: Tina ALBERTSON, Brian CHRISTIN, Jacob Randolph GARCIA, Christopher Glen RAMSBORG, Claire L. SUTHERLAND, Clinton WEBER, Rachel K. YOST, Mark J. GILBERT, He LI
-
Publication number: 20230131940Abstract: Provided herein are methods of assessing or determining the presence or absence of particles, such as bead particles, present in a cell composition. Also provided are articles of manufacture and kits for use in the methods.Type: ApplicationFiled: December 20, 2022Publication date: April 27, 2023Applicant: Juno Therapeutics, Inc.Inventors: Kien KHUU-DUONG, Calvin CHAN, Rachel K. YOST, Brian CHRISTIN, Ruth BERRY, Janelle STOOPS
-
Patent number: 11633426Abstract: Provided are methods for administering multiple doses of cells, such as T cells, to subjects for cell therapy. Also provided are compositions and articles of manufacture for use in the methods. The cells generally express recombinant receptors such as chimeric receptors, e.g., chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). The methods generally involve administering a first and at least one consecutive dose of the cells. Timing of the doses relative to one another, and/or size of the doses, in some embodiments provide various advantages such as lower or reduced toxicity and improved efficacy, for example, due to increased exposure of the subject to the administered cells. In some embodiments, the first dose is a relatively low dose, such as one that reduces tumor or disease burden, thereby improving the efficacy of consecutive or subsequent doses, and the consecutive dose is a consolidating dose.Type: GrantFiled: October 29, 2019Date of Patent: April 25, 2023Assignee: Juno Therapeutics, Inc.Inventor: Mark J. Gilbert
-
Patent number: 11623961Abstract: Provided herein are BCMA-binding molecules, including anti-BCMA antibodies and antigen-binding fragments thereof such as heavy chain variable (VH) regions and single-chain antibody fragments, and chimeric receptors comprising the anti-BCMA binding molecules such as chimeric antigen receptors (CARs). In some embodiments, the anti-BCMA antibodies or antigen-binding fragments thereof specifically bind to BCMA-1. Among the anti-BCMA antibodies are human antibodies, including those that compete for binding to BCMA with reference antibodies, such as a non-human reference antibody. Also provided are genetically engineered cells expressing the CARs or BCMA-binding molecules and uses thereof such as in adoptive cell therapy.Type: GrantFiled: November 1, 2018Date of Patent: April 11, 2023Assignee: Juno Therapeutics, Inc.Inventors: Blythe D. Sather, Steven M. Shamah, Yan Chen, Rebecca Wu, Collin Hauskins, Csaba Pazmany, Jui Dutta-Simmons, Kimberly Harrington
-
Publication number: 20230090117Abstract: Provided herein are methods for transduction of T cells. In some embodiments, the provided methods include transduction of T cells by incubation with a retroviral vector particle, e.g., lentiviral vector, in which the cells have been selected for CCR7+ expression. The provided methods improve the process for genetically engineering T cells by increasing transduction frequency and/or by reducing the variability in transduction frequency among biological samples. Also provided are resulting cells transduced with a recombinant or heterologous gene, and compositions thereof.Type: ApplicationFiled: January 27, 2021Publication date: March 23, 2023Applicant: Juno Therapeutics, Inc.Inventors: Neil HAIG, Jeffrey TEOH
-
Publication number: 20230091137Abstract: Provided are methods of detecting replication competent retrovirus in a sample containing a cell transduced with a viral vector particle encoding a recombinant and/or heterologous molecule, e.g., heterologous gene product. The methods may include assessing transcription of one or more target genes, such as viral genes, that are expressed in a retrovirus but not expressed in the viral vector particle. Replication competent retrovirus may be determined to be present if the levels of RNA of the one or more target genes is higher than a reference value, which can be measured directly or indirectly, including from a positive control sample containing RNA from the respective target gene at a known level and/or at or above the limit of detection of the assay.Type: ApplicationFiled: June 30, 2022Publication date: March 23, 2023Applicant: Juno Therapeutics, IncInventors: Allison Adin BIANCHI, Ruth BERRY
-
Publication number: 20230087953Abstract: Provided in some aspects are compositions of cells for treating subjects with disease and conditions such as multiple myeloma (MM), and related methods, compositions, uses and articles of manufacture. In some embodiments, the disease or condition is a relapsed or refractory multiple myeloma (r/r MM). The cells generally express recombinant receptors such as chimeric antigen receptors (CARs) for targeting an antigen, such as BCMA, on cells of the myeloma.Type: ApplicationFiled: February 11, 2021Publication date: March 23, 2023Applicant: Juno Therapeutics, Inc.Inventors: Matthew WESTOBY, Adrian Wrangham BRIGGS, David G. KUGLER, Robert Guy CASPARY, Calvin CHAN, Divya VARUN, Lothar GERMEROTH, Christian STEMBERGER, Mateusz Pawel POLTORAK, Keenan BASHOUR, Oleksandr BATUREVYCH, Nurgul KILAVUZ, Kristen HEGE, Michael BURGESS, Kaida WU, Ruth Amanda SALMON, Ashley KOEGEL
-
Publication number: 20230090176Abstract: The present disclosure relates in some aspects to methods, cells, and compositions for preparing cells and compositions for genetic engineering and cell therapy. Provided in some embodiments are streamlined cell preparation methods, e.g., for isolation, processing, incubation, and genetic engineering of cells and populations of cells. Also provided are cells and compositions produced by the methods and methods of their use. The cells can include immune cells, such as T cells, and generally include a plurality of isolated T cell populations or types. In some aspects, the methods arc capable of preparing of a plurality of different cell populations for adoptive therapy using fewer steps and/or resources and/or reduced handling compared with other methods.Type: ApplicationFiled: June 27, 2022Publication date: March 23, 2023Applicant: Juno Therapeutics, Inc.Inventors: Chris RAMSBORG, Mark L. BONYHADI, Calvin CHAN, Pascal BEAUCHESNE
-
Publication number: 20230071910Abstract: Provided herein are methods of administering a dose of T cells for treating subjects with indolent non-Hodgkin3 s lymphoma (NHL), and related methods, compositions, uses and articles of manufacture. The cells express a recombinant receptor such as a chimeric antigen receptor (CAR) for targeting an antigen of the lymphoma, such as CD19. In some embodiments, the methods are for treating grade 1-3 A follicular lymphoma (FL 1-3 A) or marginal zone lymphoma (MZL), including in heavily pretreated or poor-prognosis subjects, such as subjects that have relapsed after treatment with, or are refractory to treatment with, one or more prior therapies.Type: ApplicationFiled: January 22, 2021Publication date: March 9, 2023Applicant: Juno Therapeutics, Inc.Inventor: Thalia FARAZI
-
Patent number: 11590167Abstract: The present disclosure relates to methods, compositions and uses involving immunotherapies and inhibitors of a target protein tyrosine kinase in which the kinase is not IL-2-inducible T cell kinase (ITK) and/or is selected from Bruton's tyrosine kinase (BTK), tec protein tyrosine kinase (TEC), BMX non-receptor tyrosine kinase (Etk), TXK tyrosine kinase (TXK) and/or receptor tyro-sine-protein kinase ErbB4 (ErbB4). The provided methods, compositions and uses include administration of one or more such inhibitor with another agent, such as an immunotherapeutic agent targeting T cells and/or genetically engineered T cells, such as CAR-expressing T cells. Also provided are methods of manufacturing engineered cells, cells, compositions, methods of administration, nucleic acids, articles of manufacture and kits.Type: GrantFiled: December 1, 2017Date of Patent: February 28, 2023Assignees: Juno Therapeutic, Inc., ACERTA PHARMA B.V.Inventors: Michael Ports, Jim Qin, Ruth Salmon, Oleksandr Baturevych
-
Publication number: 20230053787Abstract: Provided are methods for determining the risk of toxicity (e.g., neurotoxicity) and/or the likelihood of response to a cell therapy. In some aspects, the methods generally involve assessing parameters or biomarkers (e.g., blood analytes) that are associated with toxicity and/or response. In some aspects, the methods relate to adoptive cell therapy involving the administration of doses of cells for treating subjects with certain B cell malignancies, such as chronic lymphocytic leukemia (CLL), such as relapsed or refractory CLL, or small lymphocytic lymphoma (SLL). The cells for the adoptive cell therapy generally express recombinant receptors such as chimeric antigen receptors (CARs). In some aspects, the methods can be used to identify or select subjects for treatment, for example, with a cell therapy.Type: ApplicationFiled: December 4, 2020Publication date: February 23, 2023Applicant: Juno Therapeutics, Inc.Inventors: Jason A. DUBOVSKY, Julie RYTLEWSKI, Ethan THOMPSON, Jerill THORPE
-
Patent number: 11564946Abstract: Provided herein are methods and articles of manufacture for use with cell therapy for the treatment of diseases or conditions, e.g., cancer, including for predicting and treating a toxicity. In some embodiments, the toxicity is related to cytokine release syndrome (CRS). The methods generally involve assessing a change in a factor indicative of tumor burden prior to administration of a cell therapy in a subject that is associated with and/or correlate to a risk of developing toxicity. In some aspects, the methods can be used to determine if the subject is at risk or likely at risk for developing a toxicity following administration of the cell therapy. Also provided are methods for treating a subject having a disease or condition, in some cases involving administration of the cell therapy, based on assessment of risk of developing a toxicity following administration of the therapy. Also provided herein are reagents and kits for performing the methods.Type: GrantFiled: October 31, 2018Date of Patent: January 31, 2023Assignee: Juno Therapeutics, Inc.Inventors: Tina Albertson, Jacob Randolph Garcia, He Li
-
Publication number: 20230028050Abstract: Provided are anti-idiotype antibodies that specifically recognize anti-BCMA antibody moieties, in particular, anti-BC-MA antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure further relates to uses of antiidiotype antibodies for specifically identifying and/or selecting cells expressing such recombinant receptors, such as anti-BCMA CAR T cells. The disclosure further relates to uses of anti-idiotype antibodies for specifically activating such cells.Type: ApplicationFiled: December 4, 2020Publication date: January 26, 2023Applicant: Juno Therapeutics, Inc.Inventors: Collin HAUSKINS, Kimberly HARRINGTON
-
Patent number: 11561219Abstract: Provided herein are methods of assessing or determining the presence or absence of particles, such as bead particles, present in a cell composition. Also provided are articles of manufacture and kits for use in the methods.Type: GrantFiled: August 25, 2017Date of Patent: January 24, 2023Assignee: Juno Therapeutics, Inc.Inventors: Kien Khuu-Duong, Calvin Chan, Rachel K. Yost, Brian Christin, Ruth Berry, Janelle Stoops
-
Publication number: 20220412954Abstract: Provided are methods for determining or predicting attributes of therapeutic cell compositions in connection with cell therapy. The cells of the therapeutic cell composition express recombinant receptors such as chimeric receptors, e.g. chimeric antigen receptors (CARs) or other transgenic receptors such as T cell receptors (TCRs). The methods provide for the identification of correlations between input composition (e.g., starting material derived from subjects for producing a cell therapy) attributes and therapeutic cell composition attributes.Type: ApplicationFiled: November 4, 2020Publication date: December 29, 2022Applicant: Juno Therapeutics, Inc.Inventors: Ronald James HAUSE, JR., Afshin MASHADI-HOSSEIN, Yue JIANG
-
Patent number: 11535903Abstract: Provided are methods of detecting replication competent virus, e.g., replication competent retrovirus such as gammaretrovirus or lentivirus, in a sample containing a cell transduced with a viral vector particle encoding a recombinant and or heterologous molecule, e.g., heterologous gene product. The methods may include assessing transcription of one or more target genes, such as viral genes, that are expressed in a retrovirus but not expressed in the viral vector particle. Replication competent retrovirus may be determined to be present if the levels of RNA of the one or more target genes is higher than a reference value, which can be measured directly or indirectly, including from a positive control sample containing RNA from the respective target gene at a known level and/or at or above the limit of detection of the assay.Type: GrantFiled: January 31, 2019Date of Patent: December 27, 2022Assignee: Juno Therapeutics, Inc.Inventors: Ruth Berry, Edwin Webb
-
Publication number: 20220401483Abstract: Provided are methods, compositions, uses and articles of manufacture of combination therapies involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and the use of (S)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-1-oxo-1,3-di-hydro-isoindol-2-yl]-piperidine-2,6-dione, or an enantiomer or mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, for treating subjects with disease and conditions such as certain B cell malignancies, and related methods, compositions, uses and articles of manufacture. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the disease or condition is a non-Hodgkin lymphoma (NHL), such as relapsed or refractory NHL or specific NHL subtype.Type: ApplicationFiled: November 6, 2020Publication date: December 22, 2022Applicant: Juno Therapeutics, Inc.Inventors: Michael PORTS, Jens HASSKARL, Sandrine MONTHEARD, Michael POURDEHNAD, Tim PULHAM, Jim QIN
-
Publication number: 20220392613Abstract: Provided are methods for classifying cells, such as T cells, using machine learning methods. The methods can be used to classify different subsets or types of cells in a mixed population of cells.Type: ApplicationFiled: August 28, 2020Publication date: December 8, 2022Applicant: Juno Therapeutics, Inc.Inventors: Ivie AIFUWA, Jon Charles GUNTHER, Keith RAWSON, Vanessa HASLE, David REISS
-
Patent number: 11471489Abstract: Provided herein are binding molecules, such as those that recognize or bind a peptide epitope of a cancer antigen, such as expressed on a cancer cell, including cells infected with human papilloma virus (HPV) or that contain HPV DNA sequences and/or those that recognize or bind a peptide epitope of HPV 16 E6 or E7, in the context of a major histocompatibility complex (MHC) molecule. Among the provided binding molecules are T cell receptors (TCRs) or antibodies, including antigen-binding fragments thereof, that bind or recognize such peptide epitopes. The present disclosure further relates to engineered cells comprising such binding molecules, e.g., TCRs or antibodies (and chimeric antigen receptors containing the antibodies), and uses thereof in adoptive cell therapy.Type: GrantFiled: April 3, 2019Date of Patent: October 18, 2022Assignee: Juno Therapeutics, Inc.Inventors: Stephen Jacob Goldfless, Brian Belmont, Cameron Brandt, Alexandra Croft, David Jeffrey Huss